Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: Preliminary evidence of activity in small cell and neuroendocrine carcinomas

Cancer

Volumn 109, Issue 7, 2007, Pages 1413-1419

  Lopes Jr , Gilberto De Lima ^a   Chiappori, Alberto ^b   Simon, George ^b   Haura, Eric ^b   Sullivan, Dan ^b   Antonia, Scott ^b   Langevin, Michel ^b   Lush, Richard ^b   Rocha Lima, Caio Max ^c  

^a Johns Hopkins Singapore   (Singapore)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Carboplatin; Gemcitabine; Irinotecan; Neuroendocrine; Phase I; Small cell lung cancer

Indexed keywords

AMINOTRANSFERASE; CARBOPLATIN; GEFITINIB; GEMCITABINE; IRINOTECAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; KIDNEY FAILURE; LIVER FAILURE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SMALL CELL CARCINOMA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS;

EID: 33947511117     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22522     Document Type: Article

References (16)

1. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-422.
2. Hainsworth JD, Burris HA, Erland JD, et al. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin and gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer. 1999;85:1269-1276.
3. Heinemann V, Hertel L, Grindey G, et al. Comparison of the cellular pharmacokinetics and toxicity of 2,2-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48:4024-4031.
4. Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs. 2996;14:243-247.
5. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12:1527-1531.
6. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19:1501-1518.
7. Cancer Therapy Evaluation Program. DCTD, NCI, NIH, DHHS. Common Toxicity Criteria. Available at: http://ctep. cancer.gov/forms/CTCv20_4-30-992.pdf Accessed January 3, 2006.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
9. Dobbie M, Hofer S, Oberholzer M, Herrmann R. Veno-occulusive disease of the liver induced by gemcitabine [letter]. Ann Oncol. 1998;9:681.
10. Coeman DC, Verbeken EK, Nackaerts KL, Demedts MG, Vansteenkiste JF. A fatal case of cholestatic liver failure probably related to gemcitabine [letter]. Ann Oncol. 2000;11:1503.
11. Robinson K, Lambiase L, Li J, Monteiro C, Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci. 2003;48:1804-1808.
12. Kagohashi K, Funayama Y, Satoh H, Sekizawa K. Fatal hepatic failure due to gemcitabine and vinorelbine [letter]. Ann Oncol. 2003;14:960.
13. Hruban R, Sternberg S, Meyers P, Fleisher M, Menendez-Botet C, Boitnott JK. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest. 1991;9:263-268.
14. Welborn JL, Kopecky KJ, Meyers FJ, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia-a Southwest Oncology Group trial. Leukemia. 1995;9:1126-1129.
15. van Groeningen CJ, Van der Vijgh WJ, Baars JJ, Stieltjes H, Huibregtse K, Pinedo HM. Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines. Clin Cancer Res. 2000;6:1342-1346.
16. Park SH, Bang SM, Cho EK, et al. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. Oncology. 2004;66:353-357.